All In Biotech

Drug Trial Radar · NCT01785849

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis

Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

508

Actual

Start

Mar 12, 2013

Primary completion

May 22, 2014

Study completion Jun 12, 2014

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.

Conditions

  • Hyperparathyroidism, Secondary

Interventions

  • EtelcalcetideDrug

    Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.

  • PlaceboDrug

    Administered intravenously (IV) three times per week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment PhaseTime frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).

Locations

118 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Pine Bluff, Arkansas

  • Research Site

    Azusa, California

  • Research Site

    Covina, California

  • Research Site

    Lakewood, California

  • Research Site

    Los Angeles, California

  • Research Site

    Lynwood, California

  • Research Site

    Northridge, California

  • Research Site

    Ontario, California

  • Research Site

    Panorama City, California

  • Research Site

    Sacramento, California

  • Research Site

    Whittier, California

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Meridian, Idaho

  • Research Site

    Evanston, Illinois

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Pontiac, Michigan

  • Research Site

    Southgate, Michigan

  • Research Site

    Tupelo, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Reno, Nevada

  • Research Site

    Amherst, New York

  • Research Site

    Brooklyn, New York

  • Research Site

    Rosedale, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Yonkers, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Allentown, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Orangeburg, South Carolina

  • Research Site

    Sumter, South Carolina

  • Research Site

    Columbia, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Fort Worth, Texas

  • Research Site

    Fort Worth, Texas

Showing 40 of 118 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.